CSI learned from Tianyao a few days ago that from the end of last year to now, the company has five or six varieties of products with varying degrees of price increases, which has not yet been reflected in the results of the first quarter, because there is a transmission period for price increases. At present, the company is planning a new round of product price increases. It is expected that the results will be reflected in the second quarter and the second half of the year, with conservative price increases of more than 25%.

These two price increases, the company's idea is to raise prices together with downstream preparation manufacturers. As Tianyao has an absolute say in corticosteroid raw materials, it works with downstream manufacturers to raise prices against the market and change the relationship between supply and demand. In theory, for every dime raised by the price of the downstream preparation enterprises, the whole downstream enterprises will generate a profit of 100 million, and these profits will be distributed between Tianyao and downstream enterprises. In addition, starting from April this year, the company will also launch some phytosterol products one after another, which will gradually change the high cost caused by the company's reliance on diosgenin products in the past. In addition, Tianyao recently completed the replacement of the leadership, the new team is also actively strengthening mechanism building and improving the level of management, and is currently implementing the annual salary of senior management members to be linked to their respective performance; the comprehensive assessment model of combining quarterly rewards and annual assessments for middle managers, rewarding the advantages and punishing the inferior, and introducing a competitive elimination mechanism. In addition, Tianyao shares are also speeding up the pace of technological innovation and reducing product costs. At present, the company is implementing a series of internal incentive policies for technological innovation, rewarding technological innovation projects and outstanding contributors. The company does not reject the continued use of capital markets for mergers and acquisitions, but the progress is still relatively slow.